[Novel molecularly target therapies for leukemia].
Kiyoi
Hitoshi
H
Department of Infectious Diseases, Nagoya University School of Medicine.
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors*; D005663:Furans; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007938:Leukemia / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use; D011799:Quinazolines / Q000627:therapeutic use; D019311:Staurosporine / Q000031:analogs & derivatives / Q000627:therapeutic use; D051941:fms-Like Tyrosine Kinase 3 / Q000037:antagonists & inhibitors*
D000970:Antineoplastic Agents; D002227:Carbazoles; D005663:Furans; D007211:Indoles; D010879:Piperazines; D011799:Quinazolines; C119379:lestaurtinib; C464670:tandutinib; D051231:Farnesyltranstransferase; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3; D019311:Staurosporine; C059539:midostaurin